GlaxoSmithkline's malaria plan: Limit profits, open labs
Drug companies get bashed for not doing enough for killer diseases like malaria that hit the developing world even as they spent hugely on lifestyle drugs for wealthy folks. GlaxoSmithKline Chief Executive Andrew Witty says he has a plan to fix the problem. Witty says he will take about a 5 percent profit above production costs on GlaxoSmithkline's experimental malaria vaccine, now in final stage trials in Africa.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063